𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Squamous cell carcinoma of the head and neck treated with radiotherapy: Does planned neck dissection reduce the chance for successful surgical management of subsequent local recurrence?

✍ Scribed by Mendenhall, William M. ;Parsons, James T. ;Amdur, Robert J. ;Cassisi, Nicholas J. ;Million, Rodney R.


Publisher
Wiley (John Wiley & Sons)
Year
2007
Weight
224 KB
Volume
10
Category
Article
ISSN
0148-6403

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Planned neck dissection after definitive
✍ William M. Mendenhall; Douglas B. Villaret; Robert J. Amdur; Russell W. Hinerman πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 100 KB πŸ‘ 2 views

## Abstract ## Background. To define the role of planned neck dissection after definitive radiotherapy for patients with node‐positive squamous cell carcinoma of the head and neck. ## Methods. Review of the pertinent literature. ## Results. Radiotherapy alone produces a relatively high likelih

Definitive radiotherapy alone or combine
✍ Matthew C. Hull; Christopher G. Morris; Scott P. Tannehill; John W. Werning; Rob πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 99 KB πŸ‘ 2 views

## Abstract ## BACKGROUND In the current study,the authors analyzed the results of definitive radiotherapy for squamous cell carcinoma of the pharyngeal wall. ## METHODS Between 1964 and 2000, 148 patients were treated with definitive radiotherapy. All patients had a 2‐year minimum follow‐up. #

Prognostic significance of p16 in locall
✍ Harold Y. Lau; Sony Brar; Alexander C. Klimowicz; Stephanie K. Petrillo; DesirΓ©e πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 328 KB πŸ‘ 1 views

## Abstract ## Background Human papillomavirus (HPV)–related squamous cell cancer of the head and neck (SCCHN) has emerged as a distinct clinical entity. The expression of p16 protein can be used as a surrogate for HPV status. ## Methods p16 immunohistochemistry (IHC) was assessed in archival pa

Phase I and initial phase II results fro
✍ David L. Schwartz; R. Bruce Montgomery; Bevan Yueh; Michael Donahue; Yoshimi Anz πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 113 KB πŸ‘ 1 views

## Abstract ## BACKGROUND The current Phase I/II study assessed induction docetaxel/carboplatin given weekly for 4 weeks, followed by weekly docetaxel/carboplatin and concomitant boost radiotherapy (CB‐XRT) for locally advanced head and neck squamous cell carcinoma. ## METHODS Twenty patients wi